NCT07476027 2026-03-17
Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Not yet recruiting
Clinical Trials
20 trialsNCT07071155 2026-02-11
M-HArbOr
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Not yet recruiting
NCT07362602 2026-01-23
Exploratory Study on in Vivo CAR-T Therapy Targeting CD20 for the Treatment of Hematological Malignancies
The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army
Phase EARLY_PHASE1 Not yet recruiting
NCT07362732 2026-01-23
Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection
Sichuan University
Phase EARLY_PHASE1 Not yet recruiting
NCT07358195 2026-01-22
Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation
Massachusetts General Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT07185490 2026-01-20
IASO104
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Not yet recruiting
NCT07338357 2026-01-13
Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML
First Affiliated Hospital of Guangxi Medical University
Phase EARLY_PHASE1 Not yet recruiting
NCT07201727 2025-10-01
CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Not yet recruiting
NCT05779930 2025-08-15
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
Nationwide Children's Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT07123662 2025-08-14
γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant
Guangzhou Bio-gene Technology Co., Ltd
Phase EARLY_PHASE1 Not yet recruiting
NCT07117175 2025-08-12
A Clinical Study to Evaluate the Safety and Efficacy of Anti-human CD 7 CAR-NK Cell Injection in Subjects With Relapsed and Refractory CD7-positive Hematological Malignancy
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase EARLY_PHASE1 Not yet recruiting
NCT06849401 2025-05-15
The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia
Shanghai Jiao Tong University School of Medicine
Phase EARLY_PHASE1 Not yet recruiting
NCT06837389 2025-02-20
Early Clinical Study of JY306 Universal NK Cell Injection in the Treatment of Adult Relapsed or Refractory CD70+ Malignant Hematologic Tumors
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1 Not yet recruiting
NCT06786299 2025-01-22
Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia.
First Affiliated Hospital of Zhejiang University
Phase EARLY_PHASE1 Not yet recruiting
NCT06702098 2024-11-22
iNK-r/r AML
Guangzhou Ruixin Biotechnological Co., LTD
Phase EARLY_PHASE1 Not yet recruiting
NCT06559644 2024-08-19
Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia
The First Affiliated Hospital of Soochow University
Phase EARLY_PHASE1 Not yet recruiting
NCT04662788 2020-12-10
Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological Malignancies
Zhejiang University
Phase EARLY_PHASE1 Not yet recruiting
NCT04657965 2020-12-08
LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies
Zhejiang University
Phase EARLY_PHASE1 Not yet recruiting
NCT04658004 2020-12-08
NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
Zhejiang University
Phase EARLY_PHASE1 Not yet recruiting
NCT04599543 2020-10-27
IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia
Zhejiang University
Phase EARLY_PHASE1 Not yet recruiting